# IUdR/BUdR Cell Cycle Labelling

> **NCT00042250** · NA · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Chemotherapy for hematologic malignancy

## Key facts

- **NCT ID:** NCT00042250
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1992-05
- **Primary completion:** 2002-10
- **Final completion:** 2002-10
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00042250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00042250, "IUdR/BUdR Cell Cycle Labelling". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00042250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*